美国老年弥漫大B细胞淋巴瘤患者的精神健康障碍与生存:一项基于人群的研究
该研究利用SEER-Medicare数据库纳入2001年1月1日至2013年12月31日确诊、年龄67岁及以上的13244例弥漫大B细胞淋巴瘤(DLBCL)患者,其中2094例(15.8%)在确诊前存在抑郁、焦虑或两者兼有。校正社会人口学和临床特征后,这些患者的5年总生存和淋巴瘤特异性生存均更差。
要点
- 确诊前存在抑郁、焦虑或两者的老年DLBCL患者5年总生存为27.0%,无此类障碍者为37.4%(HR 1.37,95%CI 1.29-1.44)。
- 单纯抑郁者生存最差(总生存HR 1.37,95%CI 1.28-1.47;淋巴瘤特异性生存HR 1.37,95%CI 1.26-1.49)。
- 作者认为应系统筛查该人群的精神健康问题。
核心结论
- 确诊前24个月内存在抑郁、焦虑或两者的老年DLBCL患者预后更差;作者认为应对该人群进行普遍且系统的精神健康筛查,因为精神健康障碍可管理,改善这一常见合并症可能影响淋巴瘤特异性生存和总生存。
研究设计与样本
- 基于SEER-Medicare数据库的人群研究,纳入2001年1月1日至2013年12月31日在美国确诊、年龄67岁及以上的DLBCL患者13244例;用账单理赔识别DLBCL确诊前存在抑郁、焦虑或两者的患者;采用Cox比例分析比较5年总生存和淋巴瘤特异性生存,校正社会人口学和临床特征(包括DLBCL分期、结外病变和B症状)。
主要发现
- 13244例DLBCL患者中2094例(15.8%)存在抑郁、焦虑或两者;6988例(52.8%)为女性,12468例(94.1%)为白人;队列中位随访2.0年(IQR 0.4-6.9年)。
- 5年总生存:存在抑郁、焦虑或两者者为27.0%(95%CI 25.1-28.9),无此类障碍者为37.4%(95%CI 36.5-38.3),HR 1.37(95%CI 1.29-1.44);按障碍类型,单纯抑郁HR 1.37(95%CI 1.28-1.47),抑郁合并焦虑HR 1.23(95%CI 1.08-1.41),单纯焦虑HR 1.17(95%CI 1.06-1.29)。
- 5年淋巴瘤特异性生存:单纯抑郁HR 1.37(95%CI 1.26-1.49),抑郁合并焦虑HR 1.25(95%CI 1.07-1.47),单纯焦虑HR 1.16(95%CI 1.03-1.31)。
临床怎么用
- 原文未据此给出推荐;作者认为该人群需要普遍且系统的精神健康筛查,精神健康障碍可管理,改善这一常见合并症可能影响淋巴瘤特异性生存和总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mental health disorders can potentially decrease quality of life and survival in patients with cancer. Little is known about the survival implications of mental health disorders in patients with diffuse large B-cell lymphoma (DLBCL). We aimed to evaluate the effect of pre-existing depression, anxiety, or both on survival in a US cohort of older patients with DLBCL. METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare (SEER-Medicare) database, we identified patients aged 67 years or older, diagnosed with DLBCL in the USA between Jan 1, 2001, and Dec 31, 2013. We used billing claims to identify patients with pre-existing depression, anxiety, or both before their DLBCL diagnosis. We compared 5-year overall survival and lymphoma-specific survival between these patients and those without pre-existing depression, anxiety, or both using Cox proportional analyses, adjusting for sociodemographic and clinical characteristics, including DLBCL stage, extranodal disease, and B symptoms. FINDINGS: Among 13 244 patients with DLBCL, 2094 (15·8%) had depression, anxiety, or both disorders; 6988 (52·8%) were female, and 12 468 (94·1%) were White. The median follow-up for the cohort was 2·0 years (IQR 0·4-6·9 years). 5-year overall survival was 27·0% (95% CI 25·1-28·9) for patients with these mental health disorders versus 37·4% (36·5-38·3) for those with no mental health disorder (hazard ratio [HR] 1·37, 95% CI 1·29-1·44). Although survival differences between mental health disorders were modest, those with depression alone had the worst survival compared with no mental health disorder (HR 1·37, 95% CI 1·28-1·47), followed by those with depression and anxiety (1·23, 1·08-1·41), and then anxiety alone (1·17, 1·06-1·29). Individuals with these pre-existing mental health disorders also had lower 5-year lymphoma-specific survival, with depression conferring the greatest effect (1·37, 1·26-1·49) followed by those with depression and anxiety (1·25, 1·07-1·47) and then anxiety alone (1·16, 1·03-1·31). INTERPRETATION: Pre-existing depression, anxiety, or both disorders present within 24 months before DLBCL diagnosis, worsens prognosis for patients with DLBCL. Our data underscore the need for universal and systematic mental health screening for this population, as mental health disorders are manageable, and improvements in this prevalent comorbidity might affect lymphoma-specific survival and overall survival. FUNDING: American Society of Hematology, National Cancer Institute, Alan J Hirschfield Award.
引用
- Kuczmarski TM, Tramontano AC, Mozessohn L, et al. Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study. Lancet Haematol. 2023. PMID: 37271158. doi:10.1016/S2352-3026(23)00094-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。